PharmaShots | Incisive News in 3 Shots

Subscribe Now

TREMFYA

Jennifer Davidson Highlights the Data from the Phase 3 QUASAR Induction Study 1

Jennifer Davidson Highlights the Data from the Phase 3 QUASAR Induction Study 1

November 14, 2023

PharmaShots Interview: Janssen’s Soumya D. Chakravarty Shares Insights on Tremfya (guselkumab) for the Treatment of Active Psoriatic Arthritis

PharmaShots Interview: Janssen’s Soumya D. Chakravarty Shares Insights on Tremfya (guselkumab) for the Treatment of Active Psoriat...

April 25, 2022

PharmaShots Interview: Dr. Philip Mease Shares Insights on the Clinical data of Tremfya (guselkumab) Presented in The Lancet Rheumatology

PharmaShots Interview: Dr. Philip Mease Shares Insights on the Clinical data of Tremfya (guselkumab) Presented in The Lancet Rheum...

September 22, 2021

PharmaShots Interview: Janssen's Andrew Greenspan Shares Insights on the Data Presented at ACR2020

PharmaShots Interview: Janssen's Andrew Greenspan Shares Insights on the Data Presented at ACR2020

January 11, 2021

Janssen Reports Results of Tremfya (guselkumab) in Interim Analysis of P-II GALAXI 1 Study for Moderately to Severely Active Crohn's Disease

Janssen Reports Results of Tremfya (guselkumab) in Interim Analysis of P-II GALAXI 1 Study for Moderately to Severely Active Crohn...

October 12, 2020

Janssen's Tremfya (guselkumab) Receives the US FDA's Approval as the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis

Janssen's Tremfya (guselkumab) Receives the US FDA's Approval as the First Selective IL-23 Inhibitor for Active Psoriatic Arthriti...

September 11, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us